Loading...
 
Toggle Health Problems and D

No indication of association with Prostate Cancer and retinol, vitamin E or active vitamin D – Nov 2012

Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade.

Cancer Causes Control. 2012 Nov;23(11):1865-73. doi: 10.1007/s10552-012-0052-5. Epub 2012 Aug 28.
Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM.
School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK. becky.gilbert at bristol.ac.uk

PURPOSE:

Some epidemiological studies suggest that vitamin A (retinol), vitamin E, and vitamin D (total 25-hydroxyvitamin D, 25(OH)D; 1,25-dihydroxyvitamin, 1,25(OH)(2)D) are protective against prostate cancer. However, the evidence is not conclusive, with positive and null associations reported for all three vitamins. Limitations of previous studies include small sample size, lack of population controls, and reliance on self-reported dietary intake. Few studies have explored the interactions of circulating 25(OH)D with 1,25(OH)(2)D or retinol, which are biologically plausible interactions.
METHODS:

We investigated the associations of circulating retinol, vitamin E, and 1,25(OH)(2)D with PSA-detected prostate cancer risk, stage, and grade in a case-control study nested within the Prostate Testing for Cancer and Treatment (ProtecT) trial. We investigated the possibility of an interaction between 25(OH)D and 1,25(OH)(2)D and whether the previously observed association between 25(OH)D and prostate cancer may be modified by retinol levels.
RESULTS:

We included 1,433 prostate cancer cases and 1,433 healthy controls. There was no evidence of associations of circulating retinol, vitamin E, or 1,25(OH)(2)D with overall prostate cancer risk, stage (advanced vs localized), or Gleason grade (high- (≥7) vs low (<7) grade). There was no evidence of an interaction of 1,25(OH)(2)D and 25(OH)D with prostate cancer risk, stage, or grade (p interaction ≥ 0.24). The association between 25(OH)D and prostate cancer did not differ by retinol level (p interaction = 0.34).
CONCLUSIONS:

We found no evidence that retinol, vitamin E, or 1,25(OH)(2)D concentrations were associated with overall prostate cancer risk or more aggressive prostate cancer phenotypes. There was no evidence of an interaction between 25(OH)D and 1,25(OH)(2)D or retinol.

PMID: 22926301


Note: No indication in the abstract of the levels for which they found no association.
For vitamin D both the cases and controls could easily all have had very low levels.
The study did not seem to look at other factors such as Calcium - see below

See also VitaminDWiki


References in the study

  1. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301(1):39–51 CrossRef
  2. Willis MS, Wians FH (2003) The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin Chim Acta 330(1–2):57–83 CrossRef
  3. Peehl DM, Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10(2):131–140 CrossRef
  4. Mondul AM, Watters JL, Mannisto S, Weinstein SJ, Snyder K, Virtamo J, Albanes D (2011) Serum retinol and risk of prostate cancer. Am J Epidemiol 173(7):813–821 CrossRef
  5. Schenk JM, Riboli E, Chatterjee N, Leitzmann MF, Ahn J, Albanes D, Reding DJ, Wang Y, Friesen MD, Hayes RB, Peters U (2009) Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 18(4):1227–1231 CrossRef
  6. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E (2007) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 86(3):672–681
  7. World Cancer Research Fund/American Institute for Cancer R (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DC
  8. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JE (2009) Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA 301(3):102–103
  9. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16(2):83–95 CrossRef
  10. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med 229(4):277–284
  11. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JAC, Metcalfe C (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22:319–340 CrossRef
  12. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy FC, Neal DE, Lane JA, Martin RM (2012) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 131(5):1187–1196. doi:http://dx.doi.org/10.1002/ijc.27327
  13. Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33:435–445 CrossRef
  14. Need AG, O’Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BEC (2008) Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 23(11):1859–1863. doi:10.1359/jbmr.080607 CrossRef
  15. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103 CrossRef
  16. Rohde CM, Manatt M, Clagett-Dame M, DeLuca HF (1999) Vitamin A antagonizes the action of vitamin D in rats. J Nutr 129(12):2246–2250
  17. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46(17):3095–3101 CrossRef
  18. Fraser WD, Durham BH, Berry JL, Mawer EB (1997) Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann Clin Biochem 34:632–637
  19. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA 294(1):66–70 CrossRef
  20. Janssen KJM, Donders AR, Harrell FE Jr, Vergouwe Y, Chen Q, Grobbee DE, Moons KGM (2010) Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 63(7):721–727 CrossRef
  21. Royston P (2009) Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata J 9(3):466–477
  22. Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH (2011) Vitamin E and the risk of prostate cancer. JAMA 306(14):1549–1556. doi:10.1001/jama.2011.1437 CrossRef
  23. Weinstein SJ, Wright ME, Lawson KA, Snyder K, Mannisto S, Taylor PR, Virtamo J, Albanes D (2007) Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16(6):1253–1259 CrossRef
  24. Venkitaraman R, Thomas K, Grace P, Dearnaley DP, Horwich A, Huddart RA, Parker CC (2010) Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance. Tumour Biol 31(2):97–102 CrossRef
  25. Watters JL, Gail MH, Weinstein SJ, Virtamo J, Albanes D (2009) Associations between {alpha}-tocopherol, {beta}-carotene, and retinol and prostate cancer survival. Cancer Res 69(9):3833–3841 CrossRef
See any problem with this page? Report it (WORKS NOV 2021)